Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Tokyo Stock Exchange  >  Chugai Pharmaceutical Co., Ltd.    4519   JP3519400000


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Chugai Pharmaceutical : Announces 2020 3rd Quarter Results

10/23/2020 | 10:25am EST

TOKYO - Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced its financial results for the third quarter of fiscal year 2020.

'As in the second quarter, strong growth in exports and royalty revenue far outpaced the decline in domestic product sales, helping Chugai to maintain high growth in the third quarter. The launch of the first recycling antibody Enspryng in Japan and the United States was a major milestone. In terms of research and development, in-house projects that will come after Enspryng are progressing well as crovalimab and SPYK04 have advanced to new development stages. We will continue pursuing innovation based on our unique strength in science and technology to satisfy unmet medical needs and increase corporate value continuously,' said Tatsuro Kosaka, Chugai's Chairman and CEO.

Third quarter results for 2020

Despite domestic sales decreased by about 7% affected by the NHI drug price revisions and the market penetration of generic drugs, Chugai reported a double-digit growth year-on-year in both revenues and operating profit for the third quarter (Core-basis), driven by increases in overseas sales, and royalties and other operating income by approximately 40% and 60%, respectively.

Revenues increased by 13.3%. Among sales, domestic sales decreased by 6.5% since sales of mainstay products in the Oncology, Bone and joint diseases, and Renal diseases areas decreased continuously from the second quarter. This resulted from the NHI drug price revisions in April this year and the market penetration of generic drugs. Domestic sales of Enspryng, a neuromyelitis optica spectrum disorder treatment newly launched in August were JPY300 million. On the other hand, overseas sales increased by 39.3% due to an increase in export of Actemra to Roche, including those for clinical trials for COVID-19 pneumonia, and export of Hemlibra, a treatment for hemophilia A, to Roche at a regular shipment price. Royalties and other operating income increased by 63.3% due to a significant increase in royalties for Hemlibra and its profit-sharing income as well as an increase in other operating income resulting from one-time income.

Cost to sales ratio improved by 2.6 percentage points at 43.1% despite the NHI price revisions mainly due to a larger proportion of in-house products including Hemlibra in the total product mix. Operating expenses increased by 5.7% in total. Marketing and distribution expenses and general and administration expenses decreased due to lower business activities caused by the spread of COVID-19. Research and development expenses recorded a double-digit increase with the projects progressing well. Operating profit increased by 35.5% due to the strong increase in revenues and a better cost to sales ratio.

The Company also made good progress in research and development. As the main progress, Chugai submitted a regulatory application in Japan for the SMN2 splicing modifier risdiplam for the treatment of spinal muscular atrophy in October. Progresses in in-house projects included the start of a phase III clinical trial of an anti-C5 recycling antibody crovalimab in paroxysmal nocturnal hemoglobinuria, and the start of clinical development of a small molecule anticancer agent SPYK04. For nemolizumab, an anti-IL-31 receptor A humanized monoclonal antibody created by Chugai, a regulatory application was filed in Japan for the treatment of atopic dermatitis by Maruho Co., Ltd., the licensee in Japan. As for the line extensions of existing products, anti-PD-L1 humanized monoclonal antibody Tecentriq and anti-VEGF humanized monoclonal antibody Avastin have been approved for hepatocellular carcinoma and anti-HER2 antibody-tuberin polymerization inhibitor conjugate Kadcyla has been approved for postoperative adjuvant therapy of HER2-positive early breast cancer.

Initiatives for COVID-19 and impact on performance

Regarding the impact of COVID-19 on performance during the nine months under review, there were no major negative impacts on revenues and profits. However, the pandemic has been affecting the progress of certain business activities as described below.

Product supply system maintained stable by taking measures to prevent infection of employees and business partners. No impacts on the product supply have been seen both in Japan and overseas up to now.

Delay of the introduction of new products and those with additional indications, such as Tecentriq and Hemlibra, in the domestic market due to various reasons including restrained sales activities and decrease in the number of hospitalizations and outpatients.

Continuous increase in export of Hemlibra to Roche.

Significant increase in export of Actemra to Roche, including those for clinical trials for COVID-19 pneumonia.

Some expenses were curbed mainly due to cancellation of overseas travels and restrained sales activities in Japan.

No major impacts on the timing of regulatory filing or approval.

Some delays in the initiation and progress of clinical trials for projects under development. These delays are expected to be resolved in time.

No delays in drug discovery activities for high-priority projects.

Construction for Chugai Life Science Park Yokohama temporarily suspended. All construction resumed with limited impacts on the overall construction schedule.

A domestic phase III clinical trial of Actemra for COVID-19 is currently being conducted, and its impact on performance is unclear at this point.

About Core results

Chugai discloses its results on a Core basis from 2013 in conjunction with its decision to apply IFRS. Core results are the results after adjusting non-Core items to IFRS results, and are consistent with the Core concept disclosed by Roche. Core results are used by Chugai as an internal performance indicator, for explaining the underlying business performance both internally and externally, and the basis for payment-by-results such as a return to shareholders.


Tomoko Shimizu

Tel: +81-3-3273-0881

Email: pr@chugai-pharm.co.jp

(C) 2020 Electronic News Publishing, source ENP Newswire

Stocks mentioned in the article
ChangeLast1st jan.
CHUGAI PHARMACEUTICAL CO., LTD. 2.35% 4669 End-of-day quote.38.96%
ROCHE HOLDING AG -0.13% 300.15 Delayed Quote.-4.28%
09:56aChugai and DeNA Jointly Launch 'Ring Again,' a Rheumatoid Arthritis Disease A..
11/20CHUGAI PHARMACEUTICAL : Receives the Best IR Award
11/18CHUGAI PHARMACEUTICAL : Selected for the First Time in the 'DJSI World,' a Globa..
11/06CHUGAI PHARMACEUTICAL : Contributes Fourteen Thousand Tons of CO2 Emission Reduc..
10/30CHUGAI PHARMACEUTICAL : Results from the Investigator-Initiated Phase I Study of..
10/29CHUGAI PHARMACEUTICAL : Contribution of Para-transit Vehicles to Welfare Service..
10/23CHUGAI PHARMACEUTICAL : Announces 2020 3rd Quarter Results
10/22Japan stocks end lower as firmer yen, U.S. political uncertainty weigh
10/21Japanese shares fall on rising yen, U.S. political uncertainty
10/21PTC Therapeutics Says Evrysdi Approved in Brazil, Japan NDA Filed
More news
Sales 2020 762 B 7 294 M 7 294 M
Net income 2020 216 B 2 065 M 2 065 M
Net cash 2020 403 B 3 852 M 3 852 M
P/E ratio 2020 35,7x
Yield 2020 1,13%
Capitalization 7 675 B 73 525 M 73 442 M
EV / Sales 2020 9,54x
EV / Sales 2021 8,62x
Nbr of Employees 7 394
Free-Float 37,7%
Duration : Period :
Chugai Pharmaceutical Co., Ltd. Technical Analysis Chart | 4519 | JP3519400000 | MarketScreener
Technical analysis trends CHUGAI PHARMACEUTICAL CO., LTD.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 12
Average target price 4 864,75 JPY
Last Close Price 4 669,00 JPY
Spread / Highest target 34,9%
Spread / Average Target 4,19%
Spread / Lowest Target -20,8%
EPS Revisions
Tatsuro Kosaka Chairman & Chief Executive Officer
Osamu Okuda President, COO & Representative Director
Itagaki Toshiaki CFO, Manager-Information Technology & Accounting
Hisafumi Okabe Senior Executive Officer & Head-Research
Junichi Nezu Executive Officer, GM-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON-1.37%378 744
ROCHE HOLDING AG-4.28%281 946
PFIZER INC.-6.59%203 437
MERCK & CO., INC.-11.89%202 757
NOVARTIS AG-12.66%200 273